Daxxin Psoriasis Shampoo PMCF

Not Applicable

Not yet recruiting

• Conditions: Scalp Psoriasis

• Registration Number: NCT06771648
• Lead Sponsor: Daxxin AB

Brief Summary

The goal of this clinical investigation is to verify the performance and safety of the CE-marked Daxxin Psoriasis Shampoo to treat scalp psoriasis. Forty-one subjects with moderate scalp psoriasis are planned to be recruited at one site in Sweden. Subjects will be asked to use the shampoo between 3 and 7 times a week, as per the instructions for use from the manufacturer, for a period of 6 weeks.

Detailed Description

Investigational device: Daxxin Psoriasis Shampoo, Basic UDI-DI: 733116220030

Intended use: Daxxin Psoriasis Shampoo is designed to alleviate symptoms related to scalp psoriasis, such as itchiness, redness, flaking, and scratch marks

Overall design:

This is a prospective, single-arm, open-label, post-market clinical follow-up investigation designed to verify performance and safety of Daxxin Psoriasis Shampoo when used by subjects with scalp psoriasis in need of treatment. The outcome will be evaluated and incorporated in the product specific clinical evaluation report (CER) and serve as a base for continuous investigations.

Following approval from the ethical committee (EC), 41 subjects with the diagnosis of moderate scalp psoriasis will be recruited at sites in Sweden. The subjects should only use Daxxin Psoriasis Shampoo and no other shampoo during the study period.

The overall duration of the investigation is estimated to 8 months, including a 6-months recruitment period. Expected duration of each subject's participation is 6 weeks with 4 visits at site. The investigation will be considered complete when the last subject has completed the last visit.

Description of Medical Procedure:

Daxxin Psoriasis Shampoo should be used at least 3 times a week and at most once a day (7 times per week). Daxxin Psoriasis Shampoo should be used according to the instruction for use (IFU), and it is important to leave the shampoo in the hair and scalp for 2-5 minutes after massaging a generous foam.

Study Timeline

• Status Verified: 2024-12
• Study First Submitted: 2024-12-19
• Study Start: 2025-01
• Study First Submitted QC: 2025-01-07
• Last Update Submitted: 2025-01-07
• Study First Posted: 2025-01-13
• Last Update Posted: 2025-01-13
• Primary Completion: 2025-09
• Study Completion: 2025-09

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

1. Male or female ≥18 years old
2. Clinical diagnosis of moderate scalp psoriasis assessed by Psoriasis Scalp Severity Index (PSSI, moderate = 3-10)
3. At least a score of 1 grade for each symptom erythema, induration and desquamation
4. Subject is willing and able to use Daxxin Psoriasis Shampoo as directed, comply with investigation instructions, and commit to all follow-up visits for the duration of the investigation, as judged by the Investigator
5. Subject agrees to refrain from using other treatments for scalp psoriasis during the clinical investigation
6. Subject is willing and able to provide written informed consent

Exclusion Criteria

1. Known allergy or sensitivity to any component of the device
2. Use of psoriasis shampoo 2 weeks prior to enrolment
3. Use of other psoriasis scalp treatment i.e., Betnovate that could affect the study result within 4 weeks prior to enrolment
4. Use of systemic and/or biological treatment for psoriasis
5. Subject has a history of psoriasis unresponsive to topical treatments
6. Subject is pregnant, lactating at time of enrolment, or is planning to become pregnant during the study
7. Subjects with any other condition that, as judged by the investigator, may make investigation procedures inappropriate
8. Subject with alcohol or drug abuse

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
PSSI score reduction at day 42	From Day 0 (enrollment) to Day 42 after enrollment of each subject	Percentage of subjects with reduction of at least 1-grade in the PSSI (Psoriasis Scalp Severity Index) score, at Visit 4 (Day 42) compared to Day 0 (baseline).

Secondary Outcome Measures

Name	Time	Method
Subject satisfaction	Day 42 after enrollment of each subject	To evaluate subject satisfaction after using Daxxin Psoriasis Shampoo, measured with a Likert scale at Visit 4 (Day 42).
Device usability	Day 42 after enrollment of each subject	To evaluate device usability as measured by a Likert scale at Visit 4 (Day 42).
PSSI score reduction at Days 14 and 28	From Day 0 (enrollment) to Day 28 after enrollment of each subject	Percentage of subjects with reduction of at least 1-grade in the PSSI score, at Visit 2 (Day 14) and Visit 3 (Day 28) compared to Day 0 (baseline).
DLQI	From Day 0 (enrollment) to Day 42 after enrollment of each subject	Change in Quality of Life assessed with Dermatology Life Quality Index Scale (DLQI) from baseline (Day 0) to Visit 2 (Day 14), to Visit 3 (Day 28), Visit 4 (Day 42)
Safety	From the enrollment of the first subject to the last visit of the last subject, which is planned to correspond to a 8-month period	Incidence of AEs, adverse device effects (ADEs), serious adverse events (SAEs), serious adverse device effects (SADEs), and device deficiencies (DDs) throughout the clinical investigation
Scratch mark grades	From Day 0 (enrollment) to Day 42 after enrollment of each subject	Change in scratch mark grades from baseline (Day 0) to Visit 2 (Day 14), to Visit 3 (Day 28), and to Visit 4 (Day 42)
Itching	From Day 0 (enrollment) to Day 42 after enrollment of each subject	Change in subject reported itching, assessed with scalp-specific itch NRS, from baseline (Day 0) to end of treatment Visit 4 (Day 42) including weekly reports
Subject reported symptoms	From Day 0 (enrollment) to Day 42 after enrollment of each subject	Change in subject reported symptoms (itching, redness, and flaking) using Likert scale from baseline (Day 0) to Visit 2 (Day 14), to Visit 3 (Day 28), and to Visit 4 (Day 42)

Trial Locations

Locations (1)

Enheten för kliniska studier, University Hospital Region Örebro; 🇸🇪 Örebro, Sweden